Published in Arch Ophthalmol on March 01, 2000
Angioid streaks, clinical course, complications, and current therapeutic management. Ther Clin Risk Manag (2009) 1.59
Treatment of age-related macular degeneration. J R Soc Med (2004) 1.38
Vascular effects of photodynamic and pulsed dye laser therapy protocols. Lasers Surg Med (2008) 1.08
Long-term results after photodynamic therapy with verteporfin for choroidal neovascularizations secondary to inflammatory chorioretinal diseases. Graefes Arch Clin Exp Ophthalmol (2003) 1.06
Long-term results of photodynamic therapy for the treatment of choroidal neovascularization secondary to angioid streaks. Graefes Arch Clin Exp Ophthalmol (2005) 1.02
Photodynamic therapy in macular diseases of asian populations: when East meets West. Jpn J Ophthalmol (2006) 1.01
Photodynamic therapy using verteporfin in circumscribed choroidal haemangioma. Br J Ophthalmol (2003) 0.98
Intravitreal bevacizumab as a primary treatment for idiopathic choroidal neovascularization. Middle East Afr J Ophthalmol (2011) 0.96
Doxycycline-mediated inhibition of choroidal neovascularization. Invest Ophthalmol Vis Sci (2009) 0.95
[Pseudoxanthoma elasticum]. Ophthalmologe (2006) 0.92
Photodynamic therapy for inflammatory choroidal neovascularisation unresponsive to immunosuppression. Br J Ophthalmol (2005) 0.91
A prospective study of visual function and quality of life following PDT in patients with wet age related macular degeneration. Br J Ophthalmol (2004) 0.89
Long-term follow-up of choroidal neovascularization secondary to angioid streaks: case series and literature review. Clin Ophthalmol (2012) 0.89
Treatment of subfoveal choroidal neovascularisation in age related macular degeneration: focus on clinical application of verteporfin photodynamic therapy. Br J Ophthalmol (2001) 0.89
Choroidal neovascularization due to punctate inner choroidopathy: long-term follow-up and review of literature. Clin Ophthalmol (2010) 0.88
Photodynamic therapy with verteporfin for choroidal neovascularization associated with angioid streaks. Graefes Arch Clin Exp Ophthalmol (2005) 0.88
Combined photodynamic therapy and intravitreal triamcinolone injection for the treatment of choroidal neovascularisation secondary to pathological myopia: a pilot study. Br J Ophthalmol (2007) 0.87
Identifying the proportion of age related macular degeneration patients who would benefit from photodynamic therapy with verteporfin (Visudyne). Br J Ophthalmol (2002) 0.87
Optical coherence tomographic and visual results at six months after transitioning to aflibercept for patients on prior ranibizumab or bevacizumab treatment for exudative age-related macular degeneration (an American Ophthalmological Society thesis). Trans Am Ophthalmol Soc (2014) 0.86
Histological findings of a surgically excised myopic choroidal neovascular membrane after photodynamic therapy. A case report. Graefes Arch Clin Exp Ophthalmol (2004) 0.85
Photodynamic therapy: a treatment option in choroidal neovascularisation secondary to punctate inner choroidopathy. Br J Ophthalmol (2003) 0.84
[Photodynamic treatment with verteporfin for patients with idiopathic choroidal neovascularization. Two-year results]. Ophthalmologe (2004) 0.84
Photodynamic therapy: current role in the treatment of chorioretinal conditions. Eye (Lond) (2016) 0.80
Higher irradiance and photodynamic therapy for age-related macular degeneration (an AOS thesis). Trans Am Ophthalmol Soc (2008) 0.78
Photodynamic therapy for choroidal neovascularization. The Jules Gonin Lecture, Montreux, Switzerland, 1 September 2002. Graefes Arch Clin Exp Ophthalmol (2003) 0.77
The changes of multifocal electroretinography in the early stage of photodynamic therapy for choroidal neovascularization. Doc Ophthalmol (2003) 0.77
Two-year results of surgical removal of choroidal neovascular membranes related to non-age-related macular degeneration. Br J Ophthalmol (2007) 0.76
Photodynamic therapy for recurrent myopic choroidal neovascularisation after limited macular translocation surgery. Br J Ophthalmol (2003) 0.76
Is reduction in the risk of vision loss the only benefit of photodynamic therapy in predominantly classic subfoveal choroidal neovascularization? Clin Ophthalmol (2008) 0.75
Optical Coherence Tomography Angiography Of Pathological Myopia Sourced and Idiopathic Choroidal Neovascularization With Follow-Up. Medicine (Baltimore) (2016) 0.75
Photodynamic therapy with verteporfin for choroidal neovascularization in patients with angioid streaks. Korean J Ophthalmol (2007) 0.75
Treatment frequency and visual outcome in subfoveal choroidal neovascularization related to pathologic myopia treated with photodynamic therapy. Graefes Arch Clin Exp Ophthalmol (2006) 0.75
[Photodynamic therapy with verteporfin for uveal melanoma]. Ophthalmologe (2005) 0.75
How to measure and predict the molar absorption coefficient of a protein. Protein Sci (1995) 18.71
An international classification and grading system for age-related maculopathy and age-related macular degeneration. The International ARM Epidemiological Study Group. Surv Ophthalmol (1995) 10.05
Photodynamic therapy with verteporfin for choroidal neovascularization caused by age-related macular degeneration: results of a single treatment in a phase 1 and 2 study. Arch Ophthalmol (1999) 8.96
Photodynamic therapy with verteporfin for choroidal neovascularization caused by age-related macular degeneration: results of retreatments in a phase 1 and 2 study. Arch Ophthalmol (1999) 8.92
Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials-tap report 2. Arch Ophthalmol (2001) 7.60
Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy. Am J Ophthalmol (1994) 5.76
Dietary carotenoids, vitamins A, C, and E, and advanced age-related macular degeneration. Eye Disease Case-Control Study Group. JAMA (1994) 5.43
Current treatment of metastatic choroidal tumors. Oncology (Williston Park) (1989) 5.15
Identification of a (CUG)n triplet repeat RNA-binding protein and its expression in myotonic dystrophy. Nucleic Acids Res (1996) 4.75
Kerato-epithelin mutations in four 5q31-linked corneal dystrophies. Nat Genet (1997) 4.43
The long-term effects of visible light on the eye. Arch Ophthalmol (1992) 4.39
A single EFEMP1 mutation associated with both Malattia Leventinese and Doyne honeycomb retinal dystrophy. Nat Genet (1999) 3.32
Are antioxidants or supplements protective for age-related macular degeneration? Arch Ophthalmol (1994) 3.25
Development and validation of a mood measure for adolescents. J Sports Sci (1999) 3.13
Conservation. Averting lemur extinctions amid Madagascar's political crisis. Science (2014) 3.11
A full genome search in multiple sclerosis. Nat Genet (1996) 2.96
Inhibition of vascular endothelial growth factor prevents retinal ischemia-associated iris neovascularization in a nonhuman primate. Arch Ophthalmol (1996) 2.95
Structural and biological characteristics of connective tissue activating peptide (CTAP-III), a major human platelet-derived growth factor. Proc Natl Acad Sci U S A (1983) 2.92
Epidemiologic aspects of uveal melanoma. Surv Ophthalmol (1988) 2.85
Racial differences in the prevalence of age-related macular degeneration: the Baltimore Eye Survey. Ophthalmology (1999) 2.80
Bacterial keratitis: a prospective clinical and microbiological study. Br J Ophthalmol (2001) 2.78
Relationship of drusen and abnormalities of the retinal pigment epithelium to the prognosis of neovascular macular degeneration. The Macular Photocoagulation Study Group. Arch Ophthalmol (1990) 2.78
Interferon-associated retinopathy. Arch Ophthalmol (1993) 2.73
A comparison of retinal morphology viewed by optical coherence tomography and by light microscopy. Arch Ophthalmol (1997) 2.70
Infraslow oscillations modulate excitability and interictal epileptic activity in the human cortex during sleep. Proc Natl Acad Sci U S A (2004) 2.69
Amniotic membrane transplantation with or without limbal allografts for corneal surface reconstruction in patients with limbal stem cell deficiency. Arch Ophthalmol (1998) 2.68
Pigment epithelium proliferation in retinal detachment (massive periretinal proliferation). Am J Ophthalmol (1975) 2.63
Risk factors for hemiretinal vein occlusion: comparison with risk factors for central and branch retinal vein occlusion: the eye disease case-control study. Ophthalmology (1998) 2.62
Ranibizumab (Lucentis) in neovascular age-related macular degeneration: evidence from clinical trials. Br J Ophthalmol (2009) 2.60
Ocular blood flow velocity in age-related macular degeneration. Ophthalmology (1995) 2.53
[Scleral buckling surgery and pneumatic retinopexy. Techniques, indications and results]. Ophthalmologe (2008) 2.46
Intravitreous injections of vascular endothelial growth factor produce retinal ischemia and microangiopathy in an adult primate. Ophthalmology (1996) 2.41
Response of the Peritoneal Tissue to Dusts Introduced as Foreign Bodies. Am J Public Health Nations Health (1935) 2.37
Adverse reactions due to indocyanine green. Ophthalmology (1994) 2.30
Natural history of subfoveal subretinal hemorrhage in age-related macular degeneration. Retina (1996) 2.27
Enlargement of atrophy and visual acuity loss in the geographic atrophy form of age-related macular degeneration. Ophthalmology (1999) 2.26
Intravitreal bevacizumab (Avastin) for macular oedema secondary to retinal vein occlusion: 12-month results of a prospective clinical trial. Br J Ophthalmol (2008) 2.24
Evolutionary strategies for the elucidation of cis and trans factors that regulate the developmental switching programs of the beta-like globin genes. Mol Phylogenet Evol (1996) 2.17
Exposure to sunlight and other risk factors for age-related macular degeneration. Arch Ophthalmol (1989) 2.16
Sudden visual loss associated with sexual activity. Arch Ophthalmol (1995) 2.05
Evaluating new retinal imaging techniques. Arch Ophthalmol (1998) 2.03
Natural course of choroidal neovascular membranes within the foveal avascular zone in senile macular degeneration. Am J Ophthalmol (1982) 1.97
Characteristics of severe intraocular inflammation following intravitreal injection of bevacizumab (Avastin). Br J Ophthalmol (2008) 1.94
Results of anterior cruciate ligament reconstruction based on meniscus and articular cartilage status at the time of surgery. Five- to fifteen-year evaluations. Am J Sports Med (2000) 1.88
Intravitreal Avastin for macular oedema secondary to retinal vein occlusion: a prospective study. Br J Ophthalmol (2008) 1.88
Retinal manifestations of neurofibromatosis. Diagnosis and management. Arch Ophthalmol (1991) 1.88
Visualization of double-stranded RNAs from the myotonic dystrophy protein kinase gene and interactions with CUG-binding protein. Nucleic Acids Res (1999) 1.85
Nd:YAG laser photodisruption of hemorrhagic detachment of the internal limiting membrane. Am J Ophthalmol (1989) 1.84
Evaluation of prior primary malignancy as a determinant of uveal melanoma. A case-control study. Ophthalmology (1989) 1.82
Neuronal regulation of glutamate transporter subtype expression in astrocytes. J Neurosci (1997) 1.81
Retinal sparing by selective retinal pigment epithelial photocoagulation. Arch Ophthalmol (1999) 1.80
Folate deficiency in rats induces DNA strand breaks and hypomethylation within the p53 tumor suppressor gene. Am J Clin Nutr (1997) 1.75
Transient global amnesia: clinical characteristics and prognosis. Neurology (1987) 1.72
Adult human colonic subepithelial myofibroblasts express extracellular matrix proteins and cyclooxygenase-1 and -2. Am J Physiol (1997) 1.70
Serial magnetic resonance imaging findings for a spontaneously resolving spinal subdural hematoma: case report. Neurosurgery (1998) 1.69
Altered phosphorylation and intracellular distribution of a (CUG)n triplet repeat RNA-binding protein in patients with myotonic dystrophy and in myotonin protein kinase knockout mice. Proc Natl Acad Sci U S A (1997) 1.66
Vascular endothelial growth factor is sufficient to produce iris neovascularization and neovascular glaucoma in a nonhuman primate. Arch Ophthalmol (1996) 1.64
Clinical course of macular holes: the Eye Disease Case-Control Study. Arch Ophthalmol (1999) 1.64
Host factors, UV radiation, and risk of uveal melanoma. A case-control study. Arch Ophthalmol (1990) 1.62
Measuring geographic atrophy in advanced age-related macular degeneration. Invest Ophthalmol Vis Sci (1999) 1.62
Very slow EEG responses lateralize temporal lobe seizures: an evaluation of non-invasive DC-EEG. Neurology (2003) 1.59
Secondary paracentral retinal holes following internal limiting membrane removal. Br J Ophthalmol (2006) 1.59
Monochromatic ophthalmoscopy and fundus photography. The normal fundus. Arch Ophthalmol (1977) 1.58
Clinical characteristics of choroidal neovascular membranes. Arch Ophthalmol (1987) 1.57